pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,912 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1875Endpoints1455Fierce Biotech771BioSpace762BioPharma Dive550raps249onclive165fda recalls
therapy area
allOncology12965Rare Disease3357Immunology3052Cardiology2859Hematology2304Pulmonology2255Vaccines
  • US panel warns China’s biotech plan could dominate sector and threaten drug supply chain
    A congressional commission has warned that China’s new five-year biotech plan could allow it to dominate the global drug market. The commission says the strategy could leave U.S. patients vulnerab…
    BioPharma Dive · 54m agoRegulatoryNegative↗ source
  • FDA approves Regeneron's Livsayis, first RNAi therapy for generalized myasthenia gravis
    The Food and Drug Administration approved Regeneron's Livsayis, an RNA interference drug for generalized myasthenia gravis, marking the company's first marketed RNAi therapy. The drug, originally…
    BioPharma Dive · 2h agoApprovalPositive↗ source
← prev
page 1 of 77
next →
120
fda medwatch115
globenewswire health73
fda press62
1861
Psychiatry & CNS1234
Ophthalmology1138
Endocrinology & Metabolism809
Pain792
Nephrology787
  • Isomorphic Labs partners with Merck on AI-driven oncology drug discovery after $5 billion funding round
    Isomorphic Labs announced a new collaboration with Merck & Co., adding the pharma giant to its AI drug discovery partners. The agreement follows Isomorphic's recent $5 billion financing and will f…
    Fierce Biotech · 8h agoDealPositive↗ source
  • Novartis CEO says shareholders remain supportive despite recent trial setbacks
    Novartis chief executive Vas Narasimhan told Fierce that, despite a series of recent clinical setbacks, most shareholders continue to back the company’s long-term strategy. The setbacks include th…
    Fierce Biotech · 13h agoPositive↗ source
  • nChroma Bio cuts workforce by half and stops HBV cure trial
    nChroma Bio, a Boston biotech focused on epigenetic therapies, announced it is reducing its staff by roughly half. The reduction follows the decision to halt enrollment in its phase 1/2 study of C…
    Fierce Biotech · 8h agoLayoffsNegative↗ source
  • Outset Medical issues safety alert for Tablo dialysis system power cords overheat risk
    The FDA’s Center for Devices and Radiological Health has posted an Early Alert after learning that certain power cords used with Outset Medical’s Tablo hemodialysis consoles and the TabloCart with…
    fda medwatch · 12h agoRegulatoryNeutral↗ source
  • Evaxion Biotech Shifts R&D Focus Exclusively to Cancer Vaccines, Halts Infectious and Autoimmune Programs
    Evaxion Biotech announced it is ending its infectious disease and autoimmune research programs to concentrate solely on oncology. The company’s most advanced candidate is EVX-01, a therapeutic can…
    Fierce Biotech · 7h agoNeutral↗ source
  • Teva R&D chief Eric Hughes resigns as company pushes innovative medicines expansion
    Teva Pharmaceutical announced that its head of research and development, Eric Hughes, M.D., Ph.D., will resign, with his departure set to occur over the next few months. Hughes joined Teva in 2022…
    Fierce Biotech · 11h agoNeutral↗ source
  • Majority rate home diagnostic tests ‘very helpful,’ but just 33% for accuracy: DNV survey
    People are twice as likely to describe home diagnostic tests as very helpful versus them as very accurate, according to new global research from the quality assurance, risk management and certifica…
    Fierce Biotech · 17h ago↗ source
  • FDA approves Infilbray, first therapy for neurological symptoms of Type 3 Gaucher disease
    The U.S. Food and Drug Administration has approved Infilbray (venglustat) tablets for treating the neurological manifestations of Type 3 Gaucher disease in adults and children weighing at least 15…
    fda press · 22h agoApprovalPositive↗ source
  • Pfizer signs $2.6 billion deal with China's Starna to acquire in vivo CAR-T programs for autoimmune diseases
    Pfizer announced a $2.6 billion agreement with Chinese biotech Starna Therapeutics to obtain rights to three preclinical in vivo CAR-T candidates aimed at autoimmune diseases. The deal includes a…
    Fierce Biotech · 1d agoDealPositive↗ source
  • Pfizer signs $2.6 billion China deal to develop in-vivo CAR-T therapies for autoimmune disease
    Pfizer announced a collaboration with Chinese biotech Starna Therapeutics to pursue in-vivo CAR-T cell therapies aimed at autoimmune disorders. Under the agreement, Pfizer will receive exclusive r…
    BioPharma Dive · 1d agoDealPositive↗ source
  • AbbVie inks up to $2.5 billion deal with Disco to pursue bispecific cancer therapeutics
    AbbVie announced a collaboration with German biotech Disco Pharmaceuticals that could be worth up to $2.5 billion. The agreement provides a $40 million upfront payment, with the balance linked to…
    Fierce Biotech · 1d agoDealPositive↗ source
  • Biogen's tau antisense therapy shows 38% slower decline in 2-year Alzheimer extension study
    Biogen presented new data from the open‑label extension of its phase 2 Celia trial at the CTAD 2026 conference. The update focused on the tau‑targeting antisense oligonucleotide, diranersen, admini…
    Fierce Biotech · 1d agoPositive readoutPositive↗ source
  • Priavoid’s Alzheimer’s drug misses primary goal in phase 2 trial, shows later cognitive benefit signal
    German biotech Priavoid reported that its oral all-D-peptide candidate, PRI-002, did not achieve the primary efficacy endpoint in the phase 2 PRImus-AD study of patients with mild cognitive impairm…
    Fierce Biotech · 1d agoNegative readoutNegative↗ source
  • Cognito Therapeutics' Phase 3 HOPE Study Misses Primary Goal but Shows Promise in Mild Alzheimer’s Patients
    Cognito Therapeutics announced that its phase 3 HOPE trial of Spectris AD, a home-based device delivering light and sound stimulation, did not achieve its primary efficacy endpoint. The trial enro…
    Fierce Biotech · 1d agoNegative readoutNeutral↗ source
  • FDA rejects Summit Therapeutics' lung cancer drug ivonescimab, citing insufficient survival benefit
    The U.S. Food and Drug Administration issued a complete response letter rejecting the lung‑cancer therapy ivonescimab, which is being developed by Summit Therapeutics in partnership with Akeso. In…
    BioPharma Dive · 1d agoRegulatoryNegative↗ source
  • FDA clears Medtronic's MiniMed Fit tubeless insulin pump
    MiniMed, a Medtronic unit, announced that the FDA has granted clearance for its new tubeless insulin pump called MiniMed Fit. The device is designed to be worn for up to seven days and holds a 300…
    Fierce Biotech · 1d agoApprovalPositive↗ source
  • Merck halts $2.7 billion BTK inhibitor program after negative phase 3 data
    Merck announced it is discontinuing its BTK inhibitor nemtabrutinib program, ending three phase 3 trials in chronic lymphocytic leukemia and small lymphocytic lymphoma. The decision follows a reco…
    Fierce Biotech · 1d agoNegative readoutNegative↗ source
  • Big Pharma execs urge biotech firms to be transparent and patient to win deals
    At Fierce Biotech's London Life Sciences Week, representatives from five major pharmaceutical companies shared how they evaluate biotech partners. Bayer's head of business development warned that…
    Fierce Biotech · 1d agoDealNeutral↗ source
  • Experts warn of safety risks as FDA targets compounded GLP-1 weight-loss drugs sold by telehealth firms
    At the HLTH conference, experts highlighted growing concerns about telehealth companies that sell compounded GLP-1 weight-loss medications. These firms create custom formulations and ship them dir…
    BioPharma Dive · 22h agoRegulatoryNegative↗ source
  • Quanterix CEO Everett Cunningham resigns after ten months, interim leader appointed
    Quanterix announced that Everett Cunningham will leave his role as president and chief executive officer after serving less than a year. The company said he will step down to pursue another opportu…
    Fierce Biotech · 1d agoNeutral↗ source
  • White House pulls nomination for FDA nominee Overton
    The sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say.
    BioPharma Dive · 1d ago↗ source
  • FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer
    FDA approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer.
    fda press · 1d agoApprovalPositive↗ source
  • FDA clears Roche's Wilserdly pill for certain ER-positive, HER2-negative breast cancers
    The U.S. Food and Drug Administration has approved Roche's new oral therapy Wilserdly for a specific group of breast cancer patients. The drug is indicated for adults with estrogen receptor‑positi…
    BioPharma Dive · 2d agoApprovalPositive↗ source